Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for anemia in lower-risk myelodysplastic syndromes
KCT0012642Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in myelodysplastic syndrome (MDS), sponsored by Boryung. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on KCT0012642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012642.